Physician profile
Toby Mathew
NPI 1669859369
$4,729.78
in general payments reported to CMS, 2019-2025
22 companies · $536 in 2025
The $536 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $233 · 2021: $240 · 2022: $737 · 2023: $1,125 · 2024: $1,458 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,118.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $589.38 | 2019-2025 | |
| Csl Behring | $508.42 | 2019-2025 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $498.73 | 2020-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.86 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.73 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $311.04 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Astrazeneca Pharmaceuticals LP | $308.04 | 2019-2023 | Lokelma |
| Janssen Pharmaceuticals, INC | $288.35 | 2019-2024 | Xarelto |
| Ferring Pharmaceuticals INC. | $264.53 | 2023-2025 | Rebyota |
| Shionogi INC | $263.40 | 2022-2025 | Fetroja |
| Vifor Pharma, INC. | $256.46 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $136.51 | 2022-2024 | Ultomiris |
| Genzyme Corporation | $118.74 | 2024 | |
| Astellas Pharma US INC | $63.38 | 2019-2021 | |
| Insmed, INC. | $52.64 | 2023 | Arikayce |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $45.38 | 2021-2024 | |
| Vertex Pharmaceuticals Incorporated | $40.38 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $36.40 | 2019 | |
| Paratek Pharmaceuticals, INC. | $35.11 | 2024 | Nuzyra |
| Aimmune Therapeutics, INC. | $25.02 | 2025 | Vowst |
| Allergan, INC. | $24.76 | 2019 | |
| Melinta Therapeutics, LLC | $17.52 | 2024 | Rezzayo, Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.